| Literature DB >> 30202747 |
Cheng Li1, Nora Renz1, Andrej Trampuz1.
Abstract
Periprosthetic joint infection (PJI) is a serious complication after arthroplasty, which is associated with pain, prolonged hospital stay, multiple surgeries, functional incapacitation, and even mortality. Using scientific and efficient management protocol including modern diagnosis and treatment of PJI and eradication of infection is possible in a high percentage of affected patients. In this article, we review the current knowledge in epidemiology, classification, pathogenesis, diagnosis and treatment of PJI.Entities:
Keywords: Arthroplasty; Implants; Infection; Joint prosthesis
Year: 2018 PMID: 30202747 PMCID: PMC6123506 DOI: 10.5371/hp.2018.30.3.138
Source DB: PubMed Journal: Hip Pelvis ISSN: 2287-3260
Classification of Periprosthetic Joint Infection (PJI) into Acute and Chronic Infection
| Type of PJI | Acute PJI | Chronic PJI |
|---|---|---|
| Pathogenesis | ||
| - Perioperative origin | Early postoperative | Delayed postoperative (low-grade) |
| <4 weeks after surgery | ≥4 weeks after surgery | |
| - Hematogenous origin | <3 weeks of symptoms | ≥3 weeks of symptoms |
| Biofilm age (maturity) | Immature | Mature |
| Clinical features | Acute joint pain, fever, red/swollen joint | Chronic pain, loosening of the prosthesis, sinus tract (fistula) |
| Causative microorganism | High-virulent: | Low-virulent: Coagulase-negative staphylococci (e.g. |
| Surgical treatment | Débridement & retention of prosthesis (change of mobile parts) | Complete removal of prosthesis (exchange in one-, two-, or multiple stages) |
Definition of Periprosthetic Joint Infection, if at least one of the following 4 criteria is fulfilled
| Diagnostic test | Criteria | Sensitivity (%) | Specificity (%) |
|---|---|---|---|
| Clinical features | Sinus tract or visible purulence* | 20–30 | 100 |
| Histology in periprosthetic tissue | Acute inflammation in periprosthetic tissue† | 95–98 | 95–98 |
| Leukocyte count in synovial fluid‡ | >2,000/μL leukocytes or >70% granulocytes | 93–96 | 93–96 |
| Microbiology (culture) | Synovial fluid or Tissue samples§or Sonication fluid (≥50 CFU/mL)‖ | 60–80 | 97 |
| 70-85 | 92 | ||
| 85–95 | 95 |
*Metal-on-metal bearing components can simulate pus, but leukocyte count is usually normal, but metal debris visible.
†Acute inflammation defined as ≥2 granulocytes per high-power field.
‡Leukocyte cutoffs are not interpretable within 6 weeks of surgery, in rheumatic joint disease, periprosthetic fracture or luxation. Leukocyte count should be determined within 24 hours; clotted specimens are treated with 10µL hyaluronidase.
§For highly virulent organisms (e.g., Staphylococcus aureus, Escherichia coli) already one positive sample confirms infection.
‖Under antibiotics and for anaerobes, <50 colony-forming unit (CFU)/mL can be significant.
Fig. 1Treatment algorithm of periprosthetic joint infection (PJI).
Fig. 2Surgical treatment of periprosthetic joint infection (PJI).
wk: week; i.v.: intravenously; p.o.: per oral.
Antimicrobial Treatment of Periprosthetic Joint Infection
| Microorganism | Antibiotic (dose), check pathogen susceptibility | Duration | Followed by |
|---|---|---|---|
| Oxacillin-/methicillin-susceptible | Cefazolin (3×2 g, i.v.)*+Rifampin (2×450 mg, p.o.) | 2 wk | According to susceptibility, Levofloxacin (2×500 mg, p.o.) or Cotrimoxazol (3×960 mg, p.o.) or Doxycyclin (2×100 mg, p.o.) +Rifampin(2×450 mg, p.o.) |
| Oxacillin-/methicillin-resistant | Vancomycin (2×1 g, i.v.)†+Rifampin (2×450 mg. p.o.) | 2 wk | Same combination as above for oxacillin-/methicillin-susceptible staphylococci |
| Rifampicin-resistant§ | Vancomycin (2×1 g, i.v.)† | 2 wk | Long-term suppression for ≥1 yr, depending on susceptibility (e.g., with cotrimoxazol, doxycycline or clindamycin) |
| Penicillin G (4×5 million U, i.v.)* or Ceftriaxon (1×2 g, i.v.) | 2 wk | Amoxicillin (3×1,000 mg, p.o.) or Levofloxacin (2×500 mg, p.o.) (consider suppression for 1 year) | |
| Penicillin-susceptible | Ampicillin (4×2 g, i.v.)*+Gentamicin (2×60-80 mg, i.v.)‡ | 2–3 wk | Amoxicillin (3×1,000 mg, p.o.) |
| Penicillin-resistant§ | Vancomycin (2×1 g, i.v.)† or +Gentamicin (2×60-80 mg, i.v.)‡ | 2–4 wk | Linezolid (2×600 mg, p.o.), maximum 4 wk |
| Vancomycin-resistant | Individual; removal of the implant or life-long suppression necessary | ||
| Gram-negative bacteria | |||
| Enterobacteriaceae ( | Ciprofloxacin (2×750 mg, p.o.) | ||
| Nonfermenters ( | Piperacillin/tazobactam (3×4.5 g, i.v.) or Meropenem (3×1 g, i.v.) or Ceftazidim (3×2 g, i.v.)+Gentamicin (1×240 mg, i.v.) | 2–3 wk | Ciprofloxacin (2×750 mg, p.o.) |
| Ciprofloxacin-resistant§ | Depending on susceptibility: meropenem (3×1 g), colistin (3×3 million U) and/or fosfomycin (3×5 g), i.v. | Oral suppression | |
| Anaerobes | |||
| Gram-positive anaerobes ( | Penicillin G (4×5 million U, i.v.)* or Ceftriaxon (1×2 g, i.v.)+Rifampin (2×450 mg, p.o.) | 2 wk | Levofloxacin (2×500 mg, p.o.) or Amoxicillin (3×1,000 mg, p.o.)+Rifampin (2×450 mg, p.o.) |
| Gram-negative anaerobes ( | Clindamycin (3×600 mg, i.v.) | 2 wk | Metronidazol (3×500 mg, p.o.) |
| Candida spp. | |||
| Fluconazole-susceptible§ | Caspofungin (1×50 mg, 1st day: 70 mg; i.v.) | 2 wk | Fluconazole (1×400 mg, suppression for ≥1 year; p.o.) |
| Fluconazole-resistant§ | Individual (e.g., with voriconazole 2×200 mg, p.o.); removal of the implant or long-term suppression | ||
Total duration of therapy: 12 weeks, usually 2 weeks intravenously, followed by oral route.
Laboratory testing 2 times/weekly: leukocytes, C-reactive protein, creatinine/estimated glomerular filtration rate, liver enzymes (AST/SGOT and ALT/SGPT).
Dose-adjustment according to renal function and body weight (<40 kg or >100 kg); the dosages needed renal adjustment are in bold.
i.v.: intravenously; p.o.: per oral.
Rifampin is administered only after the new prosthesis is implanted, wounds are dry and drains are removed; in patients aged >75 years, the rifampicin dose should be reduced to 2×300 mg, p.o.
*In case of anaphylaxis (such as Quincke's edema, bronchospasm, anaphylactic shock) or cephalosporin allergy: vancomycin (21 g, i.v.).
†Check vancomycin trough concentration (take blood before next dose) at least 1 time/week; therapeutic range, 15–20 µg/mL.
‡Give only, if gentamicin high-level (HL) is tested susceptible (consult your microbiology laboratory). In gentamicin HL-resistant enterococci: gentamicin is exchanged with ceftriaxone (1×2 g, i.v.).
§Difficult-to-treat.